{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-25-000009","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2025-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.178587+00:00","generated_at":"2026-05-23T07:04:27.817180+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Novocure Q1 revenue $155M (+12% YoY), net loss $34.3M; CE Mark for Optune Lua NSCLC","bullets":["Revenue $155M, +12% YoY; net loss $34.3M ($0.31 loss per share); adj. EBITDA -$5.0M; cash $929M.","Active patients 4,268; Optune Gio active patients +9% to 4,162; Optune Lua patients 106 (62 NSCLC, 44 MPM).","CE Mark approved for Optune Lua with immune checkpoint inhibitors or docetaxel in metastatic NSCLC after platinum progression.","Tariff risk: up to $11M if tariffs resume post-90-day pause; up to $8M if pause extended; monitoring mitigation.","PANOVA-3 Phase 3 pancreatic cancer results accepted as late-breaking abstract at ASCO 2025; milestones H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-25-000009","json":"https://secwatch.observer/filing/0001645113-25-000009.json","markdown":"https://secwatch.observer/filing/0001645113-25-000009.md","text":"https://secwatch.observer/filing/0001645113-25-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511325000009/0001645113-25-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511325000009/nvcr-20250424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T07:04:27.817180+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}